Takeda Pharmaceutical Co Ltd (NYSE:TAK) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus target price of $23.80 for the company, according to Zacks. Zacks has also assigned Takeda Pharmaceutical an industry rank of 56 out of 255 based on the ratings given to related companies.
TAK has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Jefferies Financial Group initiated coverage on shares of Takeda Pharmaceutical in a report on Tuesday, September 24th. They set a “buy” rating on the stock. Finally, Daiwa Capital Markets cut shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a report on Thursday, August 15th.
Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 4.01% and a return on equity of 11.23%. The business had revenue of $7.73 billion for the quarter. Equities research analysts anticipate that Takeda Pharmaceutical will post 1.5 EPS for the current year.
Hedge funds have recently modified their holdings of the business. Assetmark Inc. raised its holdings in Takeda Pharmaceutical by 443.4% during the 2nd quarter. Assetmark Inc. now owns 7,445 shares of the company’s stock valued at $132,000 after acquiring an additional 6,075 shares during the period. Eagle Global Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 30.4% in the second quarter. Eagle Global Advisors LLC now owns 136,544 shares of the company’s stock worth $2,417,000 after purchasing an additional 31,872 shares during the period. Covenant Partners LLC increased its holdings in shares of Takeda Pharmaceutical by 7.6% in the second quarter. Covenant Partners LLC now owns 63,483 shares of the company’s stock worth $1,124,000 after purchasing an additional 4,480 shares during the period. Marshall Wace LLP bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $60,381,000. Finally, Northern Trust Corp increased its holdings in shares of Takeda Pharmaceutical by 23.5% in the first quarter. Northern Trust Corp now owns 4,218,850 shares of the company’s stock worth $85,939,000 after purchasing an additional 803,851 shares during the period. 4.64% of the stock is currently owned by institutional investors and hedge funds.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Story: How to find the components of the quick ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.